dizziness, balance disorders, headache
ADVERSE EFFECTS, CORTEX
All subjects received a single high‐frequency TMS intervention. TMS was administered using a magnetic stimulation device (CCY‐IA Wuhan Yiruide Co., Ltd.), attached to a focal figure‐of‐eight shape coil (each loop had a diameter of 3.5 cm). The coil was systematically displaced (mapping) over the subject's primary motor cortex until the largest consistent motor evoked potential response from the contralateral first dorsal interosseous was recorded. The resting motor threshold (RMT) of the first interosseous was defined as the minimum intensity, which elicited a motor evoked potential of 50 μV in at least five out of 10 consecutive treatments. In our study, the stimulation target was the left DLPFC, and a navigation (Visor 2™ LT, Solutions GmbH Manufacturer, USA) was used for cranial localization. The specific localization process was as follows: the subject was seated in a reclining chair with armrests of moderate height, facing the navigation infrared spectral motion tracking system, followed by coil correction and creation of an individualized head model, which was matched to the subject's skull, and then the stimulation target (left DLPFC) was located and marked based on the subject's MRI image, completing the localization operation. Each subject received only one TMS intervention at an intensity of 90% of the resting motor threshold (RMT) at a frequency of 10 Hz, with 700 pulses and a stimulation duration of 10 min. To assess the safety of the TMS intervention in this study, we used the dizziness handicap inventory (DHI) to evaluate subjects for adverse effects, including dizziness, headache, and balance disorders during standing and walking.